Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in aHUS Extension Study
NCT05795140Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2024
- Primary completion
- Jul 2032
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Started May 2024; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05795140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795140.